CD154 blockade therapy for therapeutic protein inhibitor syndrome
AssigneeBiogen, Inc.
InventorBurt Adelman
Life of this patent
Estimating the term…
Abstract
Methods and compositions for attenuating or mitigating; suppressing; preventing; delaying onset of; or, reversing exogenous protein inhibitor syndromes, exemplified by clotting factor (e.g., Factor VIII) inhibitor syndromes. The described methods use a CD40:CD154 binding interrupter, such as a CD154 blocking agent, to attenuate or ameliorate counter-adaptive, bioinhibitory humoral immunity directed against an exogenous protein of therapeutic value.
Claims20
A method of attenuating severity of exogenous protein inhibitor syndrome, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to a subject afflicted with, or at risk of, said syndrome.
A method of suppressing adverse effects of exogenous protein inhibitor syndrome, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to a subject afflicted with, or at risk of, said syndrome.
A method of preventing development of exogenous protein inhibitor syndrome, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to a subject afflicted with, or at risk of, said syndrome.
A method of delaying onset of exogenous protein inhibitor syndrome, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to a subject afflicted with, or at risk of, said syndrome.
A method of inhibiting development of exogenous protein inhibitor syndrome, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to a subject afflicted with, or at risk of, said syndrome.
A method of reversing exogenous protein inhibitor syndrome, comprising the step of administering an effective amount of a CD40:CD154 binding interruptor to a subject afflicted with, or at risk of, said syndrome.
A method of preserving therapeutic activity of an exogenous protein, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to a subject being treated with said exogenous protein.
A method of restoring therapeutic activity of an exogenous protein, comprising the step of administering an effective amount of a CD40:CD154 binding interruptor to a subject being treated with said exogenous protein, to which the subject has developed an immune response.
Dependencies are inferred from the claim text.